| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The William Harvey Research Institute, Barts and the London, Queen Mary’s School of Medicine and Dentistry, Charterhouse Square, London, U.K. and
* Unit of Critical Care Medicine, Royal Brompton Hospital, Imperial College School of Medicine, London, U.K.
2Correspondence: The William Harvey Research Institute, Barts & the London, Charterhouse Square, London EC1M 6BQ, U.K. E-mail: t.d.warner{at}qmul.ac.uk
The beneficial actions of nonsteroidal anti-inflammatory drugs (NSAIDs) have been linked to their ability to inhibit inducible COX-2 at sites of inflammation, and their side effects (e.g., gastric damage) to inhibition of constitutive COX-1. Selective inhibitors of COX-2, such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, and valdecoxib have been developed and the greatest recent growth in our knowledge in this area has been come from the clinical use of these compounds. Although clinical data indicate that COX-2 selectivity is associated with a reduction in severe gastrointestinal events, they also reveal there are roles for constitutive COX-2 within tissues such as the brain, kidney, pancreas, intestine, and blood vessels. We now better understand the roles of COX-1 and COX-2 in functions as disparate as the perception of pain and the progression of cancers. Clinical use of COX-2-selective compounds has ignited strong debates regarding potential side effects, most notably those within the cardiovascular system such as myocardial infarctions, strokes, and elevation in blood pressure. This review will discuss how the latest studies help us understand the roles of COX-1 and COX-2 and what clinically proven benefits the newer generation of COX-2-selective inhibitors offer.—Warner, T. D., Mitchell, J. A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
Key Words: cyclooxygenase-2 • nonsteroidal anti-inflammatory drugs • rofecoxib • celecoxib • thrombosis
This article has been cited by other articles:
|
|
 |
|
  M.-R. Pan, M.-F. Hou, H.-C. Chang, and W.-C. Hung Cyclooxygenase-2 Up-regulates CCR7 via EP2/EP4 Receptor Signaling Pathways to Enhance Lymphatic Invasion of Breast Cancer Cells J. Biol. Chem., April 25, 2008; 283(17): 11155 - 11163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Doller, E.-S. Akool, A. Huwiler, R. Muller, H. H. Radeke, J. Pfeilschifter, and W. Eberhardt Posttranslational Modification of the AU-Rich Element Binding Protein HuR by Protein Kinase C{delta} Elicits Angiotensin II-Induced Stabilization and Nuclear Export of Cyclooxygenase 2 mRNA Mol. Cell. Biol., April 15, 2008; 28(8): 2608 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-T. Hong, J. Huang, T. D. Barrett, and B. R. Lucchesi Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H145 - H155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Z. J. Chu, G. Gibson, D. David, and Y. Yen The Surgeon's Role in Cancer Prevention. The Model in Colorectal Carcinoma Ann. Surg. Oncol., November 1, 2007; 14(11): 3054 - 3069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ghosh, H. Wang, Y. Ai, E. Romeo, J. P. Luyendyk, J. M. Peters, N. Mackman, S. K. Dey, and T. Hla COX-2 suppresses tissue factor expression via endocannabinoid-directed PPAR{delta} activation J. Exp. Med., September 3, 2007; 204(9): 2053 - 2061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Aisemberg, C. Vercelli, S. Billi, M. L. Ribeiro, D. Ogando, R. Meiss, S. M. McCann, V. Rettori, and A. M. Franchi Nitric oxide mediates prostaglandins' deleterious effect on lipopolysaccharide-triggered murine fetal resorption PNAS, May 1, 2007; 104(18): 7534 - 7539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dogrul, S. E. Gulmez, M. S. Deveci, H. Gul, M. H. Ossipov, F. Porreca, and F. C. Tulunay The Local Antinociceptive Actions of Nonsteroidal Antiinflammatory Drugs in the Mouse Radiant Heat Tail-Flick Test Anesth. Analg., April 1, 2007; 104(4): 927 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Antman, J. S. Bennett, A. Daugherty, C. Furberg, H. Roberts, and K. A. Taubert Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association Circulation, March 27, 2007; 115(12): 1634 - 1642. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Albrecht Angiotensin-(1-7)-induced plasticity changes in the lateral amygdala are mediated by COX-2 and NO Learn. Mem., March 8, 2007; 14(3): 177 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Virdis, R. Colucci, M. Fornai, E. Duranti, C. Giannarelli, N. Bernardini, C. Segnani, C. Ippolito, L. Antonioli, C. Blandizzi, et al. Cyclooxygenase-1 Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries From Angiotensin II-Infused Mice Hypertension, March 1, 2007; 49(3): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ferretti, R. Gassner, Z. Wang, P. Perera, J. Deschner, G. Sowa, R. B. Salter, and S. Agarwal Biomechanical Signals Suppress Proinflammatory Responses in Cartilage: Early Events in Experimental Antigen-Induced Arthritis J. Immunol., December 15, 2006; 177(12): 8757 - 8766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Mitchell, R. Lucas, I. Vojnovic, K. Hasan, J. R. Pepper, and T. D. Warner Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events FASEB J, December 1, 2006; 20(14): 2468 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Schneider, L. E. Levesque, B. Zhang, T. Hutchinson, and J. M. Brophy Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-based, Nested Case-Control Analysis Am. J. Epidemiol., November 1, 2006; 164(9): 881 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gutierrez, S. W. Ballinger, V. M. Darley-Usmar, and A. Landar Free Radicals, Mitochondria, and Oxidized Lipids: The Emerging Role in Signal Transduction in Vascular Cells Circ. Res., October 27, 2006; 99(9): 924 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Psaty and J. D. Potter Risks and benefits of celecoxib to prevent recurrent adenomas. N. Engl. J. Med., August 31, 2006; 355(9): 950 - 952. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Miyamoto, S. Miyake, M. Mizuno, N. Oka, S. Kusunoki, and T. Yamamura Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway Brain, August 1, 2006; 129(8): 1984 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Gassel, K. M. Tobias, and S. K. Cox Disposition of deracoxib in cats after oral administration. J. Am. Anim. Hosp. Assoc., May 1, 2006; 42(3): 212 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Schroder, Y. Yudina, A. Sabirsh, N. Zahn, J. Z. Haeggstrom, and J. Stein 15-deoxy-{Delta}12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells J. Lipid Res., May 1, 2006; 47(5): 1071 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Sooriakumaran COX-2 inhibitors and the heart: are all coxibs the same? Postgrad. Med. J., April 1, 2006; 82(966): 242 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kardosh, N. Soriano, Y.-T. Liu, J. Uddin, N. A. Petasis, F. M. Hofman, T. C. Chen, and A. H. Schonthal Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib Blood, December 15, 2005; 106(13): 4330 - 4338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Mandal, Z. Zhang, S.-J. Kim, P.-C. Tsai, and A. B. Mukherjee Cutting Edge: Yin-Yang: Balancing Act of Prostaglandins with Opposing Functions to Regulate Inflammation J. Immunol., November 15, 2005; 175(10): 6271 - 6273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Carey, J. A. Bradbury, J. M. Seubert, R. Langenbach, D. C. Zeldin, and D. R. Germolec Contrasting Effects of Cyclooxygenase-1 (COX-1) and COX-2 Deficiency on the Host Response to Influenza A Viral Infection J. Immunol., November 15, 2005; 175(10): 6878 - 6884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kankuri, D. Cholujova, M. Comajova, A. Vaheri, and J. Bizik Induction of Hepatocyte Growth Factor/Scatter Factor by Fibroblast Clustering Directly Promotes Tumor Cell Invasiveness Cancer Res., November 1, 2005; 65(21): 9914 - 9922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zamora, A. Grishin, C. Wong, P. Boyle, J. Wang, D. Hackam, J. S. Upperman, K. J. Tracey, and H. R. Ford High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod Am J Physiol Gastrointest Liver Physiol, October 1, 2005; 289(4): G643 - G652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Mandal, R. Ray, Z. Zhang, B. Chowdhury, N. Pattabiraman, and A. B. Mukherjee Uteroglobin Inhibits Prostaglandin F2{alpha} Receptor-mediated Expression of Genes Critical for the Production of Pro-inflammatory Lipid Mediators J. Biol. Chem., September 23, 2005; 280(38): 32897 - 32904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Crokart, K. Radermacher, B. F. Jordan, C. Baudelet, G. O. Cron, V. Gregoire, N. Beghein, C. Bouzin, O. Feron, and B. Gallez Tumor Radiosensitization by Antiinflammatory Drugs: Evidence for a New Mechanism Involving the Oxygen Effect Cancer Res., September 1, 2005; 65(17): 7911 - 7916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman, D. DeMets, and J. Loscalzo Cyclooxygenase Inhibition and Cardiovascular Risk Circulation, August 2, 2005; 112(5): 759 - 770. [Full Text] [PDF]
|
|
|
|
|
|
L. Johansson, A. Rytkonen, H. Wan, P. Bergman, L. Plant, B. Agerberth, T. Hokfelt, and A.-B. Jonsson Human-Like Immune Responses in CD46 Transgenic Mice J. Immunol., July 1, 2005; 175(1): 433 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Juni, S. Reichenbach, and M. Egger COX 2 inhibitors, traditional NSAIDs, and the heart BMJ, June 11, 2005; 330(7504): 1342 - 1343. [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Brown and A. Rashid Cancer Prevention: The Importance of Accurate Risk Assessment Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1357 - 1358. [Full Text] [PDF]
|
|
|
|
|
|
X. Tong, L. Yin, S. Joshi, D. W. Rosenberg, and C. Giardina Cyclooxygenase-2 Regulation in Colon Cancer Cells: MODULATION OF RNA POLYMERASE II ELONGATION BY HISTONE DEACETYLASE INHIBITORS J. Biol. Chem., April 22, 2005; 280(16): 15503 - 15509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Kim, Y.-H. Kim, K.-J. Shin, Y.-S. Oh, C. S. Lee, K.-O. Kang, S. H. Ryu, and P.-G. Suh 2,2',4,6,6'-Pentachlorobiphenyl-Induced Apoptosis Is Limited by Cyclooxygenase-2 Induction Toxicol. Sci., February 1, 2005; 83(2): 397 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Turrin and S. Rivest Unraveling the Molecular Details Involved in the Intimate Link between the Immune and Neuroendocrine Systems Experimental Biology and Medicine, November 1, 2004; 229(10): 996 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Warner, I. Vojnovic, F. Giuliano, R. Jimenez, D. Bishop-Bailey, and J. A. Mitchell Cyclooxygenases 1, 2, and 3 and the Production of Prostaglandin I2: Investigating the Activities of Acetaminophen and Cyclooxygenase-2-Selective Inhibitors in Rat Tissues J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 642 - 647. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
